Active-ingredient Dossier
Atomoxetine Hydrochloride
Active-ingredient Dossier for Atomoxetine Hydrochloride (selective noradrenaline reuptake inhibitor). Australian brands, products, PBS listings, PBAC…
- Brand: APO-ATOMOXETINE
- Brand: Atomoxetine-WGR
- Brand: ATOMOXETINE SANDOZ
- Brand: ATOMOXETINE
- Brand: STRATAMOX
- Therapeutic area: Psychiatry
- Therapeutic area: Neurology
What is
Atomoxetine Hydrochloride Atomoxetine Hydrochloride is a selective noradrenaline reuptake inhibitor.
Australian brands containing
Atomoxetine Hydrochloride — APO-ATOMOXETINE — Atomoxetine-WGR — ATOMOXETINE SANDOZ — ATOMOXETINE — STRATAMOX
Therapeutic areas
Atomoxetine Hydrochloride is registered in Neurology (4 brands) and Psychiatry (1 brand).
Sponsor landscape
The ingredient is marketed by three sponsors: Arrotex Pharmaceuticals, Sandoz, and GM Pharma.
PBS and regulatory activity
One brand containing Atomoxetine Hydrochloride has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is from 1 March 2016, with two brands having PBAC outcomes recorded. No AusPARs are on record for this ingredient.